Jeff E. Knight - 26 Jul 2022 Form 4 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)

Role
Chief Operating Officer
Signature
/s/ Marc Wilson, as attorney-in-fact
Issuer symbol
CRNX
Transactions as of
26 Jul 2022
Net transactions value
-$3,756
Form type
4
Filing time
29 Jul 2022, 16:26:53 UTC
Previous filing
02 Mar 2022
Next filing
27 Jan 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRNX Common Stock Other $20,091 +1,152 +23% $17.44 6,102 20 May 2022 Direct F1
transaction CRNX Common Stock Sale $23,847 -1,152 -19% $20.70 4,950 26 Jul 2022 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares purchased under Crinetics Pharmaceuticals, Inc. 2018 Employee Stock Purchase Plan in a transaction exempt from Section 16(b) pursuant to Rule 16b-3(c).
F2 The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $20.7004 per share. The range of actual sales prices on the transaction date was $20.69 to $20.7016 per share. Detailed information on the exact number of shares sold at each price can be obtained from the issuer upon request.